Synergy Pharmaceuticals Inc. (SGYP), Monday reported fourth-quarter net loss of $12.0 million or $0.18 per share, wider than $5.6 million or $0.12 per share last year.
Analysts polled by Thomson Reuters estimated loss of $0.16 per share for the quarter. Analysts' estimates typically exclude one-time items.
Research and development costs for the quarter increased to $9.1 million from $5.7 million last year. General and administrative expenses rose to $2.4 million from $2.2 million last year.
For comments and feedback: editorial@rttnews.com